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Control of Human African trypanosomiasis (HAT) relies
on diagnosis and treatment of infected individuals, and
vector control. None of the diagnostic tests for HAT are
produced commercially, and the available ones suffer
from inadequate sensitivity and specificity. There is little
interest to invest in diagnostics for neglected diseases such
as HAT, a disease of poverty that is confined to specific
foci in rural Africa. The Foundation for Innovative New
Diagnostics (FIND) is working with partners to develop
new tools for HAT. Two types of tests are being developed:
1) a test for infection with Trypanosoma brucei gambiense
and/or T.b. rhodesiense and 2) a staging test to determine
whether the central nervous system (CNS) is affected, and
to guide treatment and follow-up. Staging HAT is essential
as the drugs that treat patients with brain involvement are
quite toxic. Staging involves a lumbar puncture, which is
invasive and painful. The cut-off criteria for staging have
an intermediate area of uncertainty, and treated patients
have to be followed for 24 months to confirm cure.
A number of feasibility projects are going on, focusing on
parasite separation from blood and CSF, serological and
molecular tests, and staging of the disease. The miniature
anion exchange centrifugation technique (mAECT) kit for
separation of parasites has been improved and its manu-
facture re-established in a disease endemic country. Devel-
opment of a robust and affordable Primostar iLED
fluorescence microscope that is ideal for African settings
has improved prospects for better diagnosis of HAT. The
microscope is being evaluated for viewing trypanosomes
stained with Acridine Orange, and later with parasite-spe-
cific markers. The markers include labeled single-chain
variable fragment antibodies, aptamers and nanobodies,
which are also undergoing feasibility testing in detecting
trypanosome antigens. Screening of recombinant and
synthetic antigens for the development of an antibody
detection test will result in selection of the best to be used
in developing the test. The feasibility of using the loop-
mediated isothermal amplification (LAMP) of DNA in
diagnosis of HAT has been proven, and development into
a kit is to start soon.
New methods for staging and follow-up are being
explored, with very encouraging results. These range from
improvement of existing tests, marker validation, to dis-
covery research. Special attention is being given to speed,
simplicity, cost and reliability of the tests, as well as
reduced invasiveness.
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